Floatz logo

Pioglitazone

End Stage Renal Disease

University of UtahSmall moleculeN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the End Stage Renal Disease cohort.

Asset / SponsorPhaseRating
LIDOCAINE
The First People's Hospital of Lianyungang
Phase 4BB
ROPIVACAINE
The First People's Hospital of Lianyungang
Phase 4BB
VITAMIN D
University of Sao Paulo General Hospital
Phase 4BB
FLUOXETINE
University of Arkansas
Phase 4BB
Capsaicin
Emma Aitken
Phase 4BB

View all 24 →

Same molecule, other indications

Pioglitazone is also rated in:

diabetes mellitusDormant
BBB
Indicative ·
79 / 100
View asset →
metabolic dysfunction-associated steatohepatitisDormant
BBB
Indicative ·
75 / 100
View asset →
abdominal obesity-metabolic syndromeDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →